Chem. J. Chinese Universities ›› 2013, Vol. 34 ›› Issue (10): 2279.doi: 10.7503/cjcu20130528

• Analytical Chemistry • Previous Articles     Next Articles

Detection of Micro-metastatic Lymph Node in Thyroid Cancer by Fourier Transform Infrared Spectroscopy

LIU Ya-Qi1,2, SANG Chang-Ye3, XU Yi-Zhuang4, XU Zhi1, ZHOU Xiao-Si1, LING Xiao-Feng1   

  1. 1. Department of General Surgery, Third Hospital of Peking University, Beijing 100191, China;
    2. Department of General Surgery, Beijing Jishuitan Hospital, Beijing 100035, China;
    3. Department of General Surgery, Beijing Yanqing Hospital, Beijing 102100, China;
    4. College of Chemistry Molecular Engineering, Peking University, Beijing 100871, China
  • Received:2013-06-05 Online:2013-10-10 Published:2013-10-10

Abstract:

Sixteen non-and micro-metastatic freshly removed lymph nodes were measured by Fourier transform infrared spectrometor(FTIR) equipped with attenuated total reflectance(ATR) probe. For each spectrum, 38 variables of 13 bands including peak positions, relative intensities and full width at half maximum(FWHM) were compared between the two groups. The results indicated that the FTIR spectra of micro-metastatic lymph nodes were significantly different from non-metastatic in the bands related to protein, lipid, carbohydrate and nucleic acid. The relative intensity ratios of I3280/I1460, I1640/I1460 that related to protein increased significantly; the FWHM of F1640 increased, on the contrary, F1546 decreased significantly. The relative intensity ratios of I1400/I1460 that related to lipid increased significantly. The relative intensity ratio of I1165/I1460 that related to carbohydrate decreased significantly. The relative intensity ratio of I1240/I1460 that related to nucleic acid increased significantly. FTIR spectroscopy could be a potential powerful approach formicro-metastatic lymph nodes detection during the operation of thyroid cancer.

Key words: Thyroid cancer, Micro-metastatic, Lymph node, Fourier transform infrared spectroscopy

CLC Number: 

TrendMD: